How is Cannabidivarin (CBDV) Different from Cannabidiol (CBD)?

Aug 18

2 min read

One of the most notable differences between CBD and CBDV is their availability. While CBD is found in abundance across various cannabis and hemp strains, CBDV is much rarer. Typically, CBDV makes up less than 1% of the total cannabinoid content in most cannabis strains, which makes its extraction more challenging and costly. This rarity not only limits its availability but also elevates its status as a cannabinoid with specialized applications.

KEY TAKEAWAYS

Molecular Structure

CBD (Cannabidiol):
- Longer side chain
- Well-researched and widely studied
CBDV (Cannabidivarin):
- Shorter side chain
- Emerging focus for unique therapeutic effects, particularly in neurological conditions like ASD

Focus of Research

CBD (Cannabidiol):
- Primarily studied for anxiety, pain management, and epilepsy treatment
CBDV (Cannabidivarin):
- Targeted research on Autism Spectrum Disorder (ASD), showing promise in addressing core symptoms

Availability

CBD (Cannabidiol):
- Commonly found in many strains, forming a significant part of the cannabinoid profile
CBDV (Cannabidivarin):
- Rare, often representing less than 1% of the cannabinoid content, highlighting its specialty status

Therapeutic Applications

CBD (Cannabidiol):
- Broadly used across multiple conditions, from general wellness to specific ailments
CBDV (Cannabidivarin):
- Potentially more precise in its application, especially for improving social interaction and reducing repetitive behaviors in ASD

Side Effects

CBD (Cannabidiol):
- Typically mild side effects, such as drowsiness or changes in appetite
CBDV (Cannabidivarin):
- Early studies suggest a favorable profile with similar side effects as CBD and potentially fewer severe side effects when compared to traditional ASD treatments

Both CBD and CBDV Do NOT Produce a High

CBD (Cannabidiol):
- Does not produce psychoactive effects, making it safe for use without the risk of intoxication
CBDV (Cannabidivarin):
- Also non-psychoactive, ensuring no "high" or intoxicating effects

Why CBDV is Being Studied Extensively for Autism

Though CBD has been extensively studied and used in treatments for conditions such as anxiety and epilepsy, early research into CBDV is unveiling a potential niche for this cannabinoid in addressing core symptoms of ASD. Preclinical studies suggest that CBDV may be particularly effective in improving social behaviors and reducing irritability in animal models of autism. These findings, while promising, still require further validation through clinical trials to determine whether these benefits translate to human patients.

Conclusion

Both CBD and CBDV offer significant therapeutic potential, especially for neurological conditions. However, CBDV’s emerging profile, particularly its potential for treating ASD, suggests it could play a unique role in future therapies. Its targeted effects on autism symptoms, fewer side effects, and promising early results make it a cannabinoid worth watching. Despite its rarity, ongoing research and cultivation efforts may eventually make CBDV more accessible, expanding its use in clinical settings.

References

Zamberletti, E., Rubino, T., & Parolaro, D. (2021). Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder. Pharmacology & Therapeutics, 107878.
ClinicalTrials.gov. (2023). Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD). Clinical Trial Information.
Silva Junior, E. A., Medeiros, W. M. B., Torro, N., et al. (2022). Cannabis and cannabinoid use in autism spectrum disorder: a systematic review. Trends in Psychiatry and Psychotherapy, 44, e20200149.